Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLI1 | P08151 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2534477 | 0.98 | GLI1 (0.35) | GLI1CTSBCTSSCTSKATM | |
| SCHEMBL2539812 | 0.98 | GLI1 (0.35) | GLI1CTSBCTSSCTSKATM | |
| SCHEMBL2542483 | 0.94 | GLI1 (0.37) | GLI1CTSBCTSSCTSK | |
| SCHEMBL2540271 | 0.87 | — | — | |
| SCHEMBL2337264 | 0.76 | — | — | |
| SCHEMBL1868510 | 0.73 | — | — | |
| SCHEMBL1864575 | 0.73 | — | — | |
| SCHEMBL1864577 | 0.73 | — | — | |
| SCHEMBL2536297 | 0.72 | — | — | |
| SCHEMBL5966226 | 0.71 | POLB (0.36) | POLBHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3311835-B1 | ADMINISTRATION OF HYPOXIA ACTIVATED PRODRUGS AND ANTIANGIOGENIC AGENTS FOR THE TREATMENT OF CANCER | THRESHOLD PHARMACEUTICALS INC (US) | 2021-03-24 | — | — | EP | disclosed |
| EP-3311835-A1 | ADMINISTRATION OF HYPOXIA ACTIVATED PRODRUGS AND ANTIANGIOGENIC AGENTS FOR THE TREATMENT OF CANCER | Threshold Pharmaceuticals Inc. (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-2593139-B1 | ADMINISTRATION OF HYPOXIA ACTIVATED PRODRUGS AND ANTIANGIOGENIC AGENTS FOR THE TREATMENT OF CANCER | THRESHOLD PHARMACEUTICALS INC (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-2336141-B1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| CN-103458896-B | Be used for the treatment of the method for cancer | THRESHOLD PHARMACEUTICALS, INC. (US) | 2016-02-10 | — | — | CN | disclosed |
| US-9254299-B2 | Administration of hypoxia activated prodrugs in combination with Chk1 inhibitors for treating cancer | THRESHOLD PHARMACEUTICALS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-9226932-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2016-01-05 | — | — | US | disclosed |
| WO-2015171647-A1 | TREATMENT OF CANCER | THRESHOLD PHARMACEUTICALS, INC. (US) | 2015-11-12 | — | — | WO | disclosed |
| CN-102746336-B | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2015-08-19 | — | — | CN | disclosed |
| US-20150005262-A1 | HYPOXIA ACTIVATED PRODRUGS AND MTOR INHIBITORS FOR TREATING CANCER | THRESHOLD PHARMACEUTICALS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-6451804-B1 | Heteroalkylamino-substituted bicyclic nitrogen heterocycles | SYNTEX (U.S.A.) LLC | 2002-09-17 | — | — | US | disclosed |
| EP-1228070-A1 | HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2002-08-07 | — | — | EP | disclosed |
| EP-1226144-A1 | ALKYLAMINO SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-31 | — | — | EP | disclosed |
| US-20020082276-A1 | Quinoline derivatives as anti-inflammatory agents | SNYTEX (U.S.A.) LLC | 2002-06-27 | — | — | US | disclosed |
| WO-2002041843-A2 | ANTIINFLAMMATION AGENTS | TULARIK INC. (US) | 2002-05-30 | — | — | WO | disclosed |
| US-20020052349-A1 | p-(sulfonyl) aryl and heteroarylamines as anti-inflammatory agents | SYNTEX (U.S.A.) LLC | 2002-05-02 | — | — | US | disclosed |
| WO-2002012192-A1 | QUINOLENE DERIVATIVES AS ANTI-INFLAMMATION AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-14 | — | — | WO | disclosed |
| WO-2001083434-A2 | P-(SULFONYL)-ARYL AND HETEROARYLS AMINES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-08 | — | — | WO | disclosed |
| WO-2001029041-A1 | ALKYLAMINO SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
| WO-2001029042-A1 | HETEROALKYLAMINO-SUBSTITUTED BICYCLIC NITROGEN HETEROCYCLES AS INHIBITORS OF P38 PROTEIN KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082276-A1 | Quinoline derivatives as anti-inflammatory agents | CNR1, CNR2, PTGER4 | GLI1 2270/4885CTSB 1203/4885CTSS 592/4885 |
| US-20020052349-A1 | p-(sulfonyl) aryl and heteroarylamines as anti-inflammatory agents | PTGES, P2RX3, P2RX7 | GLI1 583/4885CTSB 606/4885CTSS 499/4885 |
| US-20150005262-A1 | HYPOXIA ACTIVATED PRODRUGS AND MTOR INHIBITORS FOR TREATING CANCER | HIF1AN, HIF1A, MTOR | GLI1 833/4885CTSB 1028/4885CTSS 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.